LTLeen Timbermont

Leen Timbermont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leen Timbermont has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The blood transcriptional response in patients developing intensive care unit-acquired pneumonia

    by Justin de Brabander, Erik H.A. Michels, Joe M. Butler, Tom D.Y. Reijnders, Tjitske S.R. van Engelen, Giuseppe G.F. Leite, Fleur P. Paling, Augustijn M. Klarenbeek, Daoud L.S. Sie, Roxane E. Boyer, et al.

    Background: Immune response dysregulation has been implicated in the development of intensive care unit (ICU)-acquired pneumonia. We aimed to determine differences in the longitudinal blood transcriptional response between patients who develop ICU-acquired pneumonia (cases) and those who do not (controls).Methods: We performed a case–cohort study in mechanically ventilated trauma and surgery patients with ICU stays >2 days, enrolled in 30 hospitals across Europe. We collected blood for RNA sequencing at baseline, day 7 and (in cases) the day of pneumonia diagnosis. We performed gene set enrichment analysis and analysed longitudinal gene expression changes using linear mixed models. External validation was performed using an independent trauma cohort.Results: We enrolled 113 cases and 115 controls, with similar baseline characteristics. At baseline (median 2 days after ICU admission), cases showed upregulated gene pathways relating to innate immunity, haemostasis and metabolism, and downregulated adaptive immune pathways. These changes persisted at the day of pneumonia diagnosis (median 6 days, compared to day 7 in controls). In the longitudinal comparison, cases exhibited enhanced upregulation of innate immunity, adaptive immunity and haemostasis pathways, along with enhanced downregulation of metabolism pathways, relative to controls (all p<0.00001, except haemostasis p<0.05). These findings were largely externally validated. Cases had higher quantitative sepsis response signature scores (p<0.001), reflective of immune dysregulation.Conclusion: Patients developing ICU-acquired pneumonia exhibit distinct blood transcriptional responses shortly after ICU admission and in the subsequent path to pneumonia, suggestive of broad immune dysfunction with both immunosuppressive and inflammatory features.


  • Open Access

    Frequent host-switch and gene exchange shape the evolution of Staphylococcus aureus ST398

    by Surbhi Malhotra-Kumar, Qiang Lin, Leen Timbermont, Jelle Vlaeminck, Minh Nguyen, Thomas van der Schalk, David Tabor, Dina Raafat, Christine Lammens, Silva Holtfreter, et al.

    Staphylococcus aureus ST398 is a typical ‘One Health’ pathobiont exemplifying multiple-host tropisms. Here we traced the evolutionary trajectory of the global accessory genome (an assembly of accessory genes) of S. aureus ST398 over 20 years, with the aim of identifying the mechanisms linking accessory genomes with multiple-host tropisms and the phylogenomic traits associated with severe human infections. We analyzed 1079 high-quality genomes of ST398 from 13 host species, spanning 23 years (1998–2021) and 25 countries across 5 continents, and showed that accessory gene pools of ST398 substantially expanded in the early period before 2010, aligning with the increase in the host-species spectrum. The more recent shifts of accessory genomes were mainly driven by stochastic processes. Accessory genes transferred widely across ST398 from different host-species and barely formed host-specific accessory gene pools, indicating that a host-jump of ST398 was followed shortly by another host-switch rather than a long-term co-evolution with a new host species to generate host-specific gene pools. Human-ST398 was a major recipient of accessory gene transfer, with more common gene transfer with ST398 from pig than other animals. Life-threatening exotoxin genes separately encoding Panton-Valentine Leukocidin and the staphylococcal enterotoxin B were abundant and exclusive to human-ST398 that showed a higher evolution rate than animal-ST398. Both accessory and core genome analyses implied nutrient metabolism as a major force for ST398 evolution. Analyses of clinical data revealed a conserved evolution of ST398 along infection development within a patient, and identified a novel subtype ST398-9 (a relatively recent phylogenetic branch) and phages StauST398_5 and StauST398_1 to be closely associated with human infections. Our findings elucidate mechanisms underlying the distribution and evolution of accessory gene pools of ST398, which determine the development of multiple-host tropisms and pathogenicity.

  • Open Access

    Correction: Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia

    by Tjitske S. R. van Engelen, Tom D. Y. Reijnders, Fleur P. Paling, Marc J. M. Bonten, Leen Timbermont, Surbhi Malhotra-Kumar, Jan A. J. W. Kluytmans, Hessel Peters-Sengers, Tom van der Poll

  • Top Cited Papers
    Open Access

    Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients

    by Julio Diaz Caballero, Rachel M. Wheatley, Natalia Kapel, Carla López-Causapé, Thomas Van der Schalk, Angus Quinn, Liam P. Shaw, Lois Ogunlana, Claudia Recanatini, Basil Britto Xavier, et al.

    Antibiotic resistance poses a global health threat, but the within-host drivers of resistance remain poorly understood. Pathogen populations are often assumed to be clonal within hosts, and resistance is thought to emerge due to selection for de novo variants. Here we show that mixed strain populations are common in the opportunistic pathogenP. aeruginosa. Crucially, resistance evolves rapidly in patients colonized by multiple strains through selection for pre-existing resistant strains. In contrast, resistance evolves sporadically in patients colonized by single strains due to selection for novel resistance mutations. However, strong trade-offs between resistance and growth rate occur in mixed strain populations, suggesting that within-host diversity can also drive the loss of resistance in the absence of antibiotic treatment. In summary, we show that the within-host diversity of pathogen populations plays a key role in shaping the emergence of resistance in response to treatment.


  • Open Access

    Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia

    by Tjitske S. R. van Engelen, Tom D. Y. Reijnders, Fleur P. Paling, Marc J. M. Bonten, Leen Timbermont, Surbhi Malhotra-Kumar, Jan A. J. W. Kluytmans, Hessel Peters-Sengers, Tom van der Poll

    Background: Immune suppression has been implicated in the occurrence of pneumonia in critically ill patients. We tested the hypothesis that Intensive Care Unit (ICU)-acquired pneumonia is associated with broad host immune aberrations in the trajectory to pneumonia, encompassing inflammatory, endothelial and coagulation responses. We compared plasma protein biomarkers reflecting the systemic host response in critically ill patients who acquire a new pneumonia (cases) with those who do not (controls). Methods: We performed a nested case–control study in patients undergoing mechanical ventilation at ICU admission with an expected stay of at least 48 h enrolled in 30 hospitals in 11 European countries. Nineteen host response biomarkers reflective of key pathophysiological domains were measured in plasma obtained on study inclusion and day 7, and—in cases—on the day of pneumonia diagnosis. Results: Of 1997 patients, 316 developed pneumonia (15.8%) and 1681 did not (84.2%). Plasma protein biomarker analyses, performed in cases and a randomly selected subgroup of controls (1:2 ratio to cases, n = 632), demonstrated considerable variation across time points and patient groups. Yet, cases showed biomarker concentrations suggestive of enhanced inflammation and a more disturbed endothelial barrier function, both at study enrollment (median 2 days after ICU admission) and in the path to pneumonia diagnosis (median 5 days after ICU admission). Baseline host response biomarker aberrations were most profound in patients who developed pneumonia either shortly (< 5 days, n = 105) or late (> 10 days, n = 68) after ICU admission. Conclusions: Critically ill patients who develop an ICU-acquired pneumonia, compared with those who do not, display alterations in plasma protein biomarker concentrations indicative of stronger proinflammatory, procoagulant and (injurious) endothelial cell responses. Trial registration: ClinicalTrials.gov Identifier: NCT02413242, posted April 9th, 2015. Graphical


  • Open Access

    Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient

    by Rachel M. Wheatley, Julio Diaz Caballero, Thomas E. van der Schalk, Fien H. R. De Winter, Liam P. Shaw, Natalia Kapel, Claudia Recanatini, Leen Timbermont, Jan Kluytmans, Mark Esser, et al.

    Bacteria have the potential to translocate between sites in the human body, but the dynamics and consequences of within-host bacterial migration remain poorly understood. Here we investigate the link between gut and lungPseudomonas aeruginosapopulations in an intensively sampled ICU patient using a combination of genomics, isolate phenotyping, host immunity profiling, and clinical data. Crucially, we show that lung colonization in the ICU was driven by the translocation ofP. aeruginosafrom the gut. Meropenem treatment for a suspected urinary tract infection selected for elevated resistance in both the gut and lung. However, resistance was driven by parallel evolution in the gut and lung coupled with organ specific selective pressures, and translocation had only a minor impact on AMR. These findings suggest that reducing intestinal colonization ofPseudomonasmay be an effective way to prevent lung infections in critically ill patients.


  • Open Access

    Combacte LAB-Net: Building a European Laboratory Network for Clinical Trials on Anti-Infectives

    by Tomislav Kostyanev, Leen Timbermont, Tuba Vilken, Christine Lammens, Surbhi Malhotra-Kumar, Youri Glupczynski, Herman Goossens

    LAB-Net, the laboratory network of COMBACTE, has established itself as an indispensable network for clinical trials in infectious diseases that plays a crucial part across 30 clinical studies not o...


  • Open Access

    Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection

    by Rachel Wheatley, Julio Diaz Caballero, Natalia Kapel, Fien H. R. de Winter, Pramod Jangir, Angus Quinn, Ester del Barrio-Tofiño, Carla López-Causapé, Jessica Hedge, Gabriel Torrens, et al.

    It is well established that antibiotic treatment selects for resistance, but the dynamics of this process during infections are poorly understood. Here we map the responses ofPseudomonas aeruginosato treatment in high definition during a lung infection of a single ICU patient. Host immunity and antibiotic therapy with meropenem suppressedP. aeruginosa, but a second wave of infection emerged due to the growth ofoprDandwbpMmeropenem resistant mutants that evolved in situ. Selection then led to a loss of resistance by decreasing the prevalence of low fitnessoprDmutants, increasing the frequency of high fitness mutants lacking the MexAB-OprM efflux pump, and decreasing the copy number of a multidrug resistance plasmid. Ultimately, host immunity suppressedwbpMmutants with high meropenem resistance and fitness. Our study highlights how natural selection and host immunity interact to drive both the rapid rise, and fall, of resistance during infection.


  • Open Access

    Exploring Virulence Factors and Alternative Therapies against Staphylococcus aureus Pneumonia

    by Jelle Vlaeminck, Dina Raafat, Kristin Surmann, Leen Timbermont, Nicole Normann, Bret Sellman, Willem J. B. van Wamel, Surbhi Malhotra-Kumar

    Pneumonia is an acute pulmonary infection associated with high mortality and an immense financial burden on healthcare systems. Staphylococcus aureus is an opportunistic pathogen capable of inducing S. aureus pneumonia (SAP), with some lineages also showing multidrug resistance. Given the high level of antibiotic resistance, much research has been focused on targeting S. aureus virulence factors, including toxins and biofilm-associated proteins, in an attempt to develop effective SAP therapeutics. Despite several promising leads, many hurdles still remain for S. aureus vaccine research. Here, we review the state-of-the-art SAP therapeutics, highlight their pitfalls, and discuss alternative approaches of potential significance and future perspectives.


  • Open Access

    Designing the ASPIRE-SSI study: a multicenter, observational, prospective cohort study to assess the incidence and risk factors of surgical site and bloodstream infections caused by Staphylococcus aureus in Europe

    by Darren P.R. Troeman, Susanne Weber, Derek Hazard, Martin Wolkewitz, Leen Timbermount, Tuba Vilken, Stephan Harbarth, Omar Ali, Frangiscos Sifakis, Jan A.J.W. Kluytmans

    Background: There is a continuing need for in-depth and updated knowledge about the epidemiology of surgical site infections (SSIs) caused by Staphylococcus aureus to support the development of effective preventive interventions. The ASPIRE-SSI study aims primarily to determine the incidence of S. aureus SSIs and postoperative bloodstream infections (BSIs) in Europe and to assess their association with patient-related, pathogen-related, and contextual risk factors. Methods: ASPIRE-SSI is a prospective, multicenter, observational cohort study primarily assessing the incidence of and risk factors for S. aureus SSI and postoperative BSI in Europe. Five thousand adult surgical patients (of which two-thirds will be S. aureus carriers and one-third non-carriers) undergoing several types of surgical procedures in sites located across Europe were enrolled in the study. Data and specimens were collected from these subjects who were followed for up to 90 days following surgery to assess study outcomes. Using advanced survival analyses and regression techniques (including competing risks models), we will determine event-specific and sub-distribution hazards to assess the independent associations of these study outcomes with risk factors. Additionally, a risk prediction model will be derived to quantify the risk of developing SSI or BSI due to S. aureus . Discussion: Despite the challenges, this study will provide important and contemporary information about the epidemiology of SSI and BSI (and other infections) caused by S. aureus in the current surgical population in Europe, thereby supporting the development of effective preventive interventions. Trial registration: clinicaltrial.gov number NCT02935244